GPC Biotech Meeting and Conference Call on Business Results for the Fiscal Year 2005 Scheduled for March 15

Martinsried/Munich (Germany), Waltham, Mass. and Princeton, N.J., March 8, 2006 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Company will hold an analyst and press meeting in Frankfurt, Germany to discuss financial results for the fiscal year 2005 and to provide a business update.
The meeting, which will be conducted in English, will be held Wednesday, March 15, 2006 at 14:00 CET/8:00 AM EST in Frankfurt.

The meeting will also be accessible via telephone or webcast. The live webcast, including synchronized slides, will be available on the GPC Biotech Web site at www.gpc-biotech.com. A replay will be available via the Web site following the live event.
Dial-in numbers for the analyst and press meeting are as follows:

Participants from Europe: 0049-69-500-71846
Participants from the U.S.: 1-800-599-9816 (toll-free)

Please dial in 10 minutes before the beginning of the meeting.
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate – satraplatin – has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at www.gpc-biotech.com.

Contact Information

Laurie Doyle

Associate Director, Investor Relations & Corporate Communications

GPC Biotech AG

Contact via E-mail